NCT00635258View on ClinicalTrials.gov

Administration of GnRH Antagonist to Oocyte Donation Recipients

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
PregnancyEmbryo Implantation
Interventions
DRUG

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)

0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.

DRUG

GnRH antagonist (Orgalutran®)

GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.

Trial Locations (1)

46004

CEGIOB, Valencia

All Listed Sponsors
collaborator

University of Valencia

OTHER

lead

Centro Ginecologia y Obstetricia.

OTHER

NCT00635258 - Administration of GnRH Antagonist to Oocyte Donation Recipients | Biotech Hunter | Biotech Hunter